Note 14 - Shareholders' Equity (Deficit)
12 Months Ended
Dec. 31, 2016
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]
1
4
. Shareholders’
Equity (
Defici
t)
 
Common stock
 
In
June
2012,
the Company issued
30,000,000
shares of common stock to
Visse
r in connection with the
Visse
r MTA (see note
3).
 
Pursuant to the terms of the Company’s Senior Convertible Notes issued in the
July
2012
Private Placement, the Company opted to pay the
twelve
monthly installment payments prior to the
September
1,
2013
maturity date with shares of the Company’s common stock. Upon final settlement, the Company had issued
163,641,547
shares of common stock at a weighted average conversion price of
$0.0774,
for the
twelve
installment payments due under the notes, consisting of
$12,000
principal and
$680
of interest
(see note
3).
 
During the year ended
December
31,
2013,
the holders of the Company’s Series A Preferred Stock converted all of the outstanding
506,936
shares of preferred stock into
16,896,070
shares of the Company’s common stock (see “Preferred stock” below). After giving effect to such conversion, the Company has
no
shares of preferred stock outstanding.
 
On
February
28,
2013,
the Company’s shareholders approved an amendment to the Certificate of Incorporation of the Company increasing the number of authorized shares of common stock from
400
million shares to
500
million shares.
 
On
October
24,
2013,
the Company’s shareholders approved an amendment to the Company’s Certificate of Incorporation increasing the number of authorized shares of common stock from
500
million shares to
700
million shares
.
 
In connection with the execution of the
2013
Purchase Agreement, the Company issued to certain investors
2,666,667
shares of the Company’s common stock. As of
December
31,
2014,
the Company had received an aggregate of
$16,000
under the
2013
Purchase Agreement through the issuance of
85,355,615
shares of its common stock at a weighted average price of
$0.19
per share. On
August
22,
2014,
the Company voluntarily terminated the
2013
Purchase Agreement, effective
August
25,
2014
(see Note
3).
 
On
September
9,
2014,
an initial registration statement covering
75,000,000
shares issued and issuable pursuant to the
2014
Purchase Agreement was declared effective by the SEC. As of
September
30,
2015,
the Company had received an aggregate of
$1,568
under the
2014
Purchase Agreement through the issuance of
12,500,000
shares of its common stock at a weighted average price of
$0.13
per share. On
March
8,
2016,
the Company voluntarily terminated the
2014
Purchase Agreement, effective
March
9,
2016
(see Note
3).
 
In connection with the execution of the
2016
Purchase Agreement
, on
March
10,
2016,
the Company issued
105,000,000
shares of the Company’s common stock, at a price of
$0.08
per share, for gross proceeds of
$8,400.
 
On
May
19,
2016,
the Company’s shareholders approved an amendment to the Company’s Certificate of Incorporation increasing the number of authorized shares of common stock from
700
million shares to
1,100
million shares.
 
On
October
26,
2016,
the Company issued and sold to the Investor of the
2016
Purchase Agreement an aggregate of
300,000,000
shares of Company’s common stock for an aggregate purchase price of
$55,000,
comprised of
200,000,000
shares at a price of
$0.15
per share and
100,000,000
shares at a price of
$0.25
per share.
 
In
2012,
the Company entered into a non-exclusive engagement agreement with an investment banking firm. The services provided by the firm did not result in the identification of any practicable investment transactions and the agreement was considered effectively terminated by the Company in
2013.
During
2016,
the Company was notified by a representative of the firm stipulating that it did not consider the engagement agreement to be terminated and that previous financings and other funding transactions completed by the Company
may
be subject to success fees. In
November
2016,
the Company reached a settlement with respect to any and all amounts allegedly due under the engagement agreement in the amount of
$750.
Such amounts have been reflected as a reduction of current year proceeds from stock issuances and a corresponding reduction to additional paid in capital.
 
Warrants
 
In connection with the Series A Preferred Stock issuances in
2009,
warrants to purchase
29,779,557
shares of the Company’s common stock, valued at
$18,179,
were outstanding through
July
15,
2015.
Due to extension of the expiration date of these warrants during
2010,
they no longer contained anti-dilution provisions and were reflected as equity as they did not meet the criteria under FASB ASC
815
for liability treatment. Such warrants had exercise prices ranging between
$0.48
and
$0.49
and expired on
July
15,
2015.